CLAIMS

1. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: $^{m}C_{es}G_{eo}{}^{m}C_{ko}T_{ds}G_{ds}A_{ds}T_{ds}T_{ds}T_{ds}G_{ds}T_{ds}{}^{m}C_{ds}{}^{m}C_{ds}G_{ko}G_{ks}G_{e}$ (SEQ ID NO: 12), wherein:

A = an adenine nucleobase,

^{m}C = a 5-methyl cytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-β-D-MOE sugar moiety,

k = a cEt sugar moiety,

d = a 2'-β-D-deoxyribosyl sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

2. The oligomeric compound of claim 1, comprising the modified oligonucleotide covalently linked to a conjugate group.

3. The oligomeric compound of claim 2, wherein the conjugate group comprises a conjugate linker consisting of a single bond.

4. The oligomeric compound of claim 2 or claim 3, wherein the conjugate group comprises a cleavable linker.

5. The oligomeric compound of any one of claims 2-4, wherein the conjugate group comprises a conjugate linker comprising 1-3 linker-nucleosides.

6. The oligomeric compound of any one of claims 2-5, wherein the conjugate group is attached to the modified oligonucleotide at the 3' and/or the 5'-end of the modified oligonucleotide.

7. The oligomeric compound of claim 2, according to the following chemical structure:



(SEQ ID NO: 12), or a salt thereof.

8. The oligomeric compound of claim 2, according to the following chemical structure:



(SEQ ID NO: 12).

9. The oligomeric compound of claim 7, which is the sodium salt or potassium salt.

10. A population of oligomeric compounds of any of claims 1-9, in which all phosphorothioate internucleoside linkages of the oligomeric compound are stereorandom.

11. A pharmaceutical composition comprising the oligomeric compound of any of claims 1-9, or the population of claim 10 and a pharmaceutically acceptable carrier or diluent.

12. The pharmaceutical composition of claim 11, wherein the pharmaceutically acceptable diluent is water or PBS.

13. Use of the pharmaceutical composition of claim 11 or claim 12, in the manufacture of a

medicament for treating a disease associated with the RAAS pathway, wherein a therapeutically effective amount of the pharmaceutical composition is to be administered to an individual having or at risk of having a disease associated with the RAAS pathway, thereby treating the disease associated with the RAAS pathway, wherein:

(i) the disease is a cardiovascular disease; and/or

(ii) the disease is selected from hypertension, resistant hypertension, Marfan syndrome, heart failure, kidney disease, obesity, metabolic syndrome, NASH, and NAFLD.

14. The use according to claim 13, wherein at least one symptom or hallmark of the disease is ameliorated, wherein the symptom or hallmark is any of hypertension, hypertensive emergency (i.e. malignant hypertension), stroke, pre-eclampsia, aneurysms of the blood vessels, abdominal aneurysm, peripheral artery disease, organ damage, or pulmonary arterial hypertension.

15. The use according to claim 13 or claim 14, wherein the pharmaceutical composition is to be administered systemically.

16. The use according to claim 15, wherein the pharmaceutical composition is to be administered subcutaneously or intramuscularly.